Business Wire·Nov 10, 2025, 4:01 PM ET

Quanterix Releases Financial Results for the Third Quarter of 2025

QTRX

Quanterix Corporation reported third-quarter 2025 revenue of $40.2 million, representing a 12.3% increase compared to $35.8 million in the prior year.
GAAP gross margin for the quarter was 42.8%, while adjusted non-GAAP gross margin was 45.9%.
The company recorded an adjusted non-GAAP EBITDA loss of $11.9 million, an increase from a $5.5 million loss in the prior year due to higher acquisition and restructuring charges.
Quanterix ended the quarter with $138.1 million in cash, cash equivalents, marketable securities, and restricted cash, with adjusted cash usage of $16.1 million.
CEO Masoud Toloue stated the company is on track to achieve $85 million in annualized synergies from the Akoya transaction and expects to reach cash flow break-even in 2026.
Operational highlights include combining sales organizations, consolidating manufacturing facilities into two sites, eliminating redundant G&A costs, and establishing new partnerships in Singapore, Taiwan, and Australia.
The company launched eight new Simoa assays in the first nine months of 2025 and introduced a new Metabolism Spike-in Module for its PhenoCycler-Fusion platform.
Full-year 2025 revenue guidance remains $130 million to $135 million, with pro forma revenue expected between $165 million and $170 million if the companies had been combined for the full year.
Quanterix expects to exit 2025 with approximately $120 million in liquid assets and anticipates 2025 adjusted cash usage of $34 million to $38 million.
A conference call to discuss these results was scheduled for November 10, 2025, at 4:30 PM ET.